FRIDAY, May 19, 2023 (HealthDay News) -- Patients with Crohn’s disease have a new treatment option, following U.S. Food and Drug Administration approval of a pill called Rinvoq (upadacitinib).

Source: https://www.gjsentinel.com/lifestyle/health_and_wellness/fda-approves-first-pill-to-treat-moderate-to-severe-crohns-disease/article_8b02bbbc-c002-5da2-bca2-17218462c453.html

Those with a clinical response to upadacitinib induction therapy were randomly assigned to 15 mg or 30 mg upadacitinib or placebo for 52 weeks in the U-ENDURE maintenance trial.

Source: https://www.gjsentinel.com/lifestyle/health_and_wellness/upadacitinib-superior-to-placebo-in-moderate-to-severe-crohn-disease/article_6de20b57-41a8-54d6-ac68-23e761d9e9c2.html

Those with a clinical response to upadacitinib induction therapy were randomly assigned to 15 mg or 30 mg upadacitinib or placebo for 52 weeks in the U-ENDURE maintenance trial.

Source: https://www.gjsentinel.com/lifestyle/health_and_wellness/upadacitinib-superior-to-placebo-in-moderate-to-severe-crohn-disease/article_6de20b57-41a8-54d6-ac68-23e761d9e9c2.html